Evidence map›Paper›PMID 33934231›Full record

ArticleVirchows Archiv : an international journal of pathology2021

Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.

Alexandre Guy, Audrey Bidet, Catherine Ling, Charline Caumont, Lisa Boureau, Jean-François Viallard, Marie Parrens

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Alexandre GuyUMR 1034, Inserm, Biology of Cardiovascular Diseases, University of Bordeaux, 33600, Pessac, France. alexandreguy29@gmail.com.ORCID http://orcid.org/0000-0002-8727-4615
Audrey BidetLaboratory of Hematology, University Hospital Center of Bordeaux, Haut-Lévêque Hospital, 33600, Pessac, France.
Catherine LingPathology Department, University Hospital Center of Bordeaux, Haut-Lévêque Hospital, 33600, Pessac, France.
Charline CaumontTumor Biology Department, University Hospital Center of Bordeaux, Haut-Lévêque Hospital, 33600, Pessac, France.
Lisa BoureauLaboratory of Hematology, University Hospital Center of Bordeaux, Haut-Lévêque Hospital, 33600, Pessac, France.
Jean-François ViallardUMR 1034, Inserm, Biology of Cardiovascular Diseases, University of Bordeaux, 33600, Pessac, France.
Marie ParrensPathology Department, University Hospital Center of Bordeaux, Haut-Lévêque Hospital, 33600, Pessac, France.
Hôpital Cardiologique du Haut-Lévêque · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BCR-ABL-fusion-negative myeloproliferative neoplasms (MPNs) with myelofibrosis (MF) include primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. Clonal extramedullary hematopoiesis (EMH) can occur during MPN pathogenesis. Although histopathological bone-marrow (BM) features during clonal EMH have been investigated, those of the spleen have been poorly described. We analyzed splenectomy samples from 28 patients with MF and BM samples from 20 of them. Slides were stained with hematoxylin and eosin, reticulin, and trichrome, with immunohistochemical labeling of glycophorin A, myeloperoxidase, CD61, CD34, and CD117. We also subjected splenectomy and BM samples from six patients and spleen samples from seven patients to next-generation sequencing (NGS). Megakaryocyte-rich spleen nodules (MRSNs), seen in seven of the 28 patients, were significantly associated with megakaryocyte proliferation in the spleen (p = 0.04). We devised a grading system for spleen fibrosis (SF) and found that SF was increased in 20 of 28 patients. Notably, patients with SF were more likely to have MRSNs, suggesting that megakaryocytes might participate in SF, as previously described in BM. Comparisons of spleen and BM NGS findings of six patients' specimens revealed identical mutational status in the two organs for half of the patients. We observed additional mutations in the spleen of two patients. However, the meaning of this finding remains unknown since there was a long interval between BM and spleen samplings (68 and 82 months, respectively).

Indexed as

AdultAgedAged, 80 and overBone MarrowDisease ProgressionFemaleFranceHematopoiesisHematopoiesis, ExtramedullaryHumansMaleMiddle AgedMyeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisSpleenImmunohistochemistryMolecular biologyMyelofibrosisSpleen pathologySplenectomy

Identifiers

PMID33934231
OpenAlexW3157991631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.